Indiana University

New Autism Drug: Carbetocin

views 5391
Air date: October 31, 2010

Host: David Crabb, MD

Mental Health Pediatrics Research
Email Email
Share Sound Medicine Share this segment
MP3 download Download MP3

Interview: Christopher McDougle, MD, Chris McDougle, chairman Department of Psychiatry; senior consultant, Christian Sarkine Autism Treatment Center



And now, a new autism medication that’s entering the clinical trial phase.

Chris McDougle, MD, is an autism specialist and professor of psychiatry at the IU School of Medicine. He speaks with Sound Medicine’s Dr. David Crabb about the new drug, called carbetocin.

Carbetocin targets the core symptoms of autism, particularly the social impairments and repetitive behaviors associated with this devastating disease. If successful, Dr. McDougle says, carbetocin could revolutionize the treatment of autism.

Dr. Chris McDougle is chair of the Department of Psychiatry at the IU School of Medicine.

Cypress Bioscience is the maker of carbetocin, which is a synthetic version of the hormone oxytocin.

If you'd like details about Dr. McDougle's research, contact the Christian Sarkine Autism Treatment Center: 317-948-9766.